Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.

Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC

First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer

BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy

Tremelimumab plus paclitaxel induced responses in metastatic urothelial cancer after progression on platinum and an immune checkpoint inhibitor.

Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Emiltatug ledadotin produced positive initial phase 1 data in breast, ovarian, and endometrial cancer, as well as adenoid cystic carcinoma type 1.

Emiltatug Ledadotin Generates Positive Initial Data in Advanced/Metastatic Solid Tumors

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.

Abenacianine Wins FDA Fast Track Designation for Tumor Visualization in the Lung

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Christopher Graham, MD, details how axatilimab has changed the care of cGVHD and highlights considerations with axatilimab, belumosudil, and ruxolitinib.

Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm 

Lucio Miele, MD, PhD of LSU has been appointed as director of the LSU-LCMC Health Cancer Center.

LSU Health Professor, Dr. Lucio Miele, Appointed as Director of LSU-LCMC Health Cancer Center

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

1rem

primary

View

Assessing Liver Function in Patients with HCC

Videos

Experts discuss the assessment of liver function in patients with hepatocellular carcinoma (HCC) while considering key data from recent clinical trials.

Rachna Shroff, MD, MS, FASCO, discusses hepatocellular carcinoma, noting its rising global incidence and identifying underlying liver cirrhosis as a key risk factor influenced by conditions like viral hepatitis and fatty liver disease; diagnosis often involves radiographic imaging and triple-phase CT and MRI scans, while treatment necessitates a multidisciplinary approach involving hepatologists, surgeons, and other specialists.

Risk Factors of Hepatocellular Carcinoma (HCC)

Drs Vogel and Singal discuss the critical importance of assessing liver function in hepatocellular carcinoma patients, as it impacts prognosis and treatment strategies; they mention the evolution from Child-Pugh scoring to the ALBI score, which uses albumin and bilirubin levels, for a more objective evaluation of liver health.

Importance of Assessing Liver Function in HCC

The ALBI score, originally developed to stratify cirrhotic patients undergoing resection, has evolved into a vital tool for assessing prognosis and treatment efficacy in various stages of hepatocellular carcinoma and is now being explored for its utility in other liver-related diseases.

Assessing Liver Function in Patients With HCC: The ALBI Score

Arndt Vogel, MD, explains that the Child-Pugh score, although simpler to calculate than the ALBI score, sometimes lacks granularity in assessing liver function in hepatocellular carcinoma patients; however, both scoring systems are considered valuable tools in clinical settings and trials for evaluating liver function's prognostic impact on treatment outcomes.

Assessing Liver Function in Patients With HCC: The Child-Pugh Score

Rachna Shroff, MD, MS, FASCO, and Amit Singal, MD, discuss the use of various liver function assessment scores—Child-Pugh, ALBI, and MELD—in the care of patients with hepatocellular carcinoma, emphasizing their pros, cons, and roles in treatment decision-making.

Assessing Liver Function in Patients With HCC: The MELD Score

Arndt Vogel, MD, discusses the post-hoc analyses of two key clinical trials focusing on the impact of liver function, measured by ALBI and Child-Pugh scores, on outcomes in hepatocellular carcinoma treatments.

Updates in First-Line Systemic Therapy for Patients With HCC

Amit Singal, MD, reviews analyses of the HIMALAYA and KEYNOTE-240 trials, focusing on the impact of liver function via ALBI grades on treatment outcomes and safety in patients with hepatocellular carcinoma.

Key Outcomes Data in Patients With HCC Based on Liver Function

Rachna Shroff, MD, MS, FASCO, shares data from the CARES-310 study showing improved progression-free and overall survival in patients with hepatocellular carcinoma treated with camrelizumab and rivoceranib compared to sorafenib, regardless of liver function.

Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310

Experts emphasize the importance of using multiple liver function assessments for more comprehensive patient evaluation in hepatocellular carcinoma treatment.

Key Outcomes Data in Patients With HCC Based on Liver Function

EP: 1.Risk Factors of Hepatocellular Carcinoma (HCC)

EP: 2.Importance of Assessing Liver Function in HCC

EP: 3.Assessing Liver Function in Patients With HCC: The ALBI Score

EP: 4.Assessing Liver Function in Patients With HCC: The Child-Pugh Score

EP: 5.Assessing Liver Function in Patients With HCC: The MELD Score

EP: 6.Updates in First-Line Systemic Therapy for Patients With HCC

EP: 7.Key Outcomes Data in Patients With HCC Based on Liver Function

EP: 8.Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310

EP: 9.The Future of Liver Function Assessments in HCC

Latest Conference Coverage